Validation of limited sampling strategy for the estimation of mycophenolic acid exposure in Chinese adult liver transplant recipients

Liver Transplantation

Volumn 13, Issue 12, 2007, Pages 1684-1693

  Chen, Hao ^a   Chen, Erzheng ^a   Mao, Anwei ^a   Yu, Zhicheng ^a   Shen, Baiyong ^a   Deng, Xiaxing ^a   Zhang, Weixia ^a   Peng, Chenghong ^a   Li, Hongwei ^a  

^a SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

[No Author keywords available]

Indexed keywords

BASILIXIMAB; DACLIZUMAB; METHYLPREDNISOLONE; MYCOPHENOLIC ACID; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; TACROLIMUS;

ACCURACY; ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; CHINESE; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG DOSE REDUCTION; DRUG EXPOSURE; FEASIBILITY STUDY; FEMALE; GRAFT RECIPIENT; HEPATITIS B; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INTERMETHOD COMPARISON; LINEAR REGRESSION ANALYSIS; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER GRAFT REJECTION; LIVER TRANSPLANTATION; MALE; MORNING DOSAGE; PREDICTION; PRIORITY JOURNAL; STATISTICAL MODEL; UNSPECIFIED SIDE EFFECT; VALIDATION STUDY;

ADRENAL CORTEX HORMONES; ADULT; AGED; AREA UNDER CURVE; ASIAN CONTINENTAL ANCESTRY GROUP; COMPUTER SIMULATION; DRUG MONITORING; DRUG THERAPY, COMBINATION; FEASIBILITY STUDIES; FEMALE; GRAFT REJECTION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LINEAR MODELS; LIVER TRANSPLANTATION; MALE; MIDDLE AGED; MODELS, BIOLOGICAL; MYCOPHENOLIC ACID; REPRODUCIBILITY OF RESULTS; TACROLIMUS;

EID: 37549061407     PISSN: 15276465     EISSN: 15276473     Source Type: Journal    
DOI: 10.1002/lt.21293     Document Type: Article

References (42)

1. Titte RS, Bruce K, Herwig-Ulf MK. Mycophenolate mofetil in solid-organ transplantation. Expert Opin Pharmacother 2003;4:2325-2345.
2. Lipsky JJ. Mycophenolate mofetil. Lancet 1996;348:1357-1359.
3. Kuypers DR, Vanrenterghem YC. Tailoring immunosuppressive therapy. Nephrol Dial Transplant 2002;17:2051-2054.
4. Cox VC, Ensom MHH. Mycophenolate mofetil for solid organ transplantation: does the evidence support the need for clinical pharmacokinetic monitoring? Ther Drug Monit 2003;25:137-157.
5. van Gelder T, Le Meur Y, Shaw LM, Oellerich M, DeNofrio D, Holt C, et al. Therapeutic drug monitoring of mycophenolate mofetil in transplantation. Ther Drug Monit 2006; 28:145-154.
6. Grasser B, Iberer F, Schaffellner S, Kniepeiss D, Stauber R, Koshsorur G, et al. Trough level-guided mycophenolate mofetil rejection prophylaxis in liver transplantation. Transplant Proc 2001;33:2154-2156.
7. van Gelder T, Hilbrands LB, Vanrenterghem Y, Weimar W, de Fijter JW, Squifflet JP, et al. A randomized doubleblind, multicenter plasma concentration controlled study of the safety and efficacy of oral mycophenolate mofetil for the prevention of acute rejection after kidney transplantation. Transplantation 1999;68:261-266.
8. Yamani MH, Starling RC, Goormastic M, Van Lente F, Smedira N, McCarthy P, et al. The impact of routine mycophenolate mofetil drug monitoring on the treatment of cardiac allograft rejection. Transplantation 2000;69:2326-2330.
9. DeNofrio D, Loh E, Kao A, Korecka M, Pickering FW, Craig KA, et al. Mycophenolic acid concentrations are associated with cardiac allograft rejection. J Heart Lung Transplant 2000; 19:1071-1076.
10. Mourad M, Malaise J, Chaib Eddour D, De Meyer M, Konig J, Schepers R, et al. Correlation of mycophenolic acid pharmacokinetic parameters with side effects in kidney transplant patients treated with mycophenolate mofetil. Clin Chem 2001;47:88-94.
11. Mourad M, Malaise J, Chaib Eddour D, De Meyer M, Konig J, Schepers R, et al. Pharmacokinetic basis for the efficient and safe use of low-dose mycophenolate mofetil in combination with tacrolimus in kidney transplantation. Clin Chem 2001;47:1241-1248.
12. van Hest RM, Mathot RA, Vulto AG, Le Meur Y, van Gelder T. Mycophenolic acid in diabetic renal transplant recipients: pharmacokinetics and application of a limited sampling strategy. Ther Drug Monit 2004;26:620-625.
13. Johnson AG, Rigby RJ, Taylor PJ, Jones CE, Allen J, Franzen K, et al. The kinetics of mycophenolic acid and its glucuronide metabolite in adult kidney transplant recipients. Clin Pharmacol Ther 1999;66:492-500.
14. Filler G. Abbreviated mycophenolic acid AUC from C0, C1, C2, and C4 is preferable in children after renal transplantation on mycophenolate mofetil and tacrolimus therapy. Transpl Int 2004;17:120-125.
15. Schutz E, Armstrong VW, Shipkova M, Weber L, Niedmann PD, Lammersdorf T, et al. Limited sampling strategy for the determination of mycophenolic acid area under the curve in pediatric kidney recipients. Transplant Proc 1998;30:1182-1184.
16. David-Neto E, Pereira Araujo LM, Sumita NM, Mendes ME, Ribeiro Castro MC, Alves CF, et al. Mycophenolic acid pharmacokinetics in stable pediatric renal transplantation. Pediatr Nephrol 2003;18:266-272.
17. Ng J, Rogosheske J, Barker J, Weisdorf D, Jacobson PA. A limited sampling model for estimation of total and unbound mycophenolic acid (MPA) area under the curve (AUC) in hematopoietic cell transplantation (HCT). Ther Drug Monit 2006;28:394-401.
18. Dosch AO, Ehlermann P, Koch A, Remppis A, Katus HA, Dengler TJ. A comparison of measured trough levels and abbreviated AUC estimation by limited sampling strategies for monitoring mycophenolic acid exposure in stable heart transplant patients receiving cyclosporin A-containing and cyclosporin A-free immunosuppressive regimens. Clin Ther 2006;28:893-905.
19. Ting LS, Villeneuve E, Ensom MH. Beyond cyclosporine: a systematic review of limited sampling strategies for other immunosuppressants. Ther Drug Monit 2006;28:419-430.
20. Chen H, Peng C, Yu Z, Shen B, Deng X, Qiu W, et al. Pharmacokinetics of mycophenolic Acid and determination of area under the curve by abbreviated sampling strategy in Chinese liver transplant recipients. Clin Pharmacokinet 2007;46;175-185.
21. Yu ZC, Cai WM, Xu D, Wang XH. HPLC determination of mycophenolate mofetil and its active metabolite mycophenolic acid in human plasma. Chin J Pharm Anal 2005;25: 381-384.
22. Sheiner LB, Beal SL. Some suggestions for measuring predictive performance. J Pharmacokinet Biopharm 1981; 9:503-512.
23. Krouwer JS, Monti KL. A simple, graphical method to evaluate laboratory assays. Eur J Clin Chem Clin Biochem 1995;33:525-527.
24. Weber LT, Hoecker B, Armstrong VW, Oellerich M, Tonshoff B. Validation of an abbreviated pharmacokinetic profile for the estimation of mycophenolic acid exposure in pediatric renal transplant recipients. Ther Drug Monit 2006;28:623-631.
25. Hale MD, Nicholls AJ, Bullingham RE, Hene R, Hoitsma A, Squifflet JP, et al. The pharmacokinetic pharmacodynamic relationship for mycophenolate mofetil in renal transplantation. Clin Pharmacol Ther 1998;64:672-683.
26. Weber LT, Shipkova M, Armstrong VW, Wagner N, Schutz E, Mehls O, et al. The pharmacokineticpharmacodynamic relationship for total and free mycophenolic acid in pediatric renal transplant recipients: a report of the German study group on mycophenolate mofetil therapy. J Am Soc Nephrol 2002;13:759-768.
27. Weber LT, Shipkova M, Armstrong VW, Wagner N, Schutz E, Mehls O, et al. Comparison of the Emit immunoassay with HPLC for therapeutic drug monitoring of mycophenolic acid in pediatric renal-transplant recipients on mycophenolate mofetil therapy. Clin Chem 2002;48:517-525.
28. Le Guellec C, Buchler M, Giraudeau B, Le Meur Y, Gakoue JE, Lebranchu Y, et al. Simultaneous estimation of cyclosporin and mycophenolic acid areas under the curve in stable renal transplant patients using a limited sampling strategy. Eur J Clin Pharmacol 2002;57:805-811.
29. Pawinski T, Hale M, Korecka M, Fitzsimmons WE, Shaw LM. Limited sampling strategy for the estimation of mycophenolic acid area under the curve in adult renal transplant patients treated with concomitant tacrolimus. Clin Chem 2002;48:1497-1504.
30. Payen S, Zhang D, Maisin A, Popon M, Bensman A, Bouissou F, et al. Population pharmacokinetics of mycophenolic acid in kidney transplant pediatric and adolescent patients. Ther Drug Monit 2005;27:378-388.
31. Fatela-Cantillo D, Hinojosa-Perez R, Peralvo-Rodriguez MI, Serrano-Diaz Canedo J, Gomez-Bravo MA. Pharmaco-kinetic evaluation of mycophenolic acid profiles during the period immediately following an orthotopic liver transplant. Transplant Proc 2006;38:2482-2485.
32. Pisupati J, Jain A, Burckart G, Hamad I, Zuckerman S, Fung J, Venkataramanan R. Intraindividual and interindividual variations in the pharmacokinetics of mycophenolic acid in liver transplant patients. J Clin Pharmacol 2005;45:34-41.
33. Manzia TM, De Liguori Carino N, Orlando G, Toti L, De Luca L, D'Andria D, et al. Use of mycophenolate mofetil in liver transplantation: a literature review. Transplant Proc 2005;37:2616-2617.
34. Aw MM, Brown NW, Itsuka T, Gonde CE, Adams JE, Heaton ND, et al. Mycophenolic acid pharmacokinetics in pediatric liver transplant recipients. Liver Transpl 2003; 9:383-388.
35. Brown NW, Aw MM, Mieli-Vergani G, Dhawan A, Tredger JM. Mycophenolic acid and mycophenolic acid glucuronide pharmacokinetics in pediatric liver transplant recipients: effect of cyclosporine and tacrolimus comedication. Ther Drug Monit 2002;24:598-606.
36. Tredger JM, Brown NW, Adams J, Gonde CE, Dhawan A, Rela M, et al. Monitoring Mycophenolate in liver transplant recipients: toward a therapeutic range. Liver Transpl 2004;10:492-502.
37. David OJ, Johnston A. Limited sampling strategies for estimating cyclosporin area under the concentration-time curve: review of current algorithms. Ther Drug Monit 2001;23:100-114.
38. Hesselink DA, van Hest RM, Mathot RA, Bonthuis F, Weimar W, de Bruin RW, et al. Cyclosporine interacts with mycophenolic acid by inhibiting the multidrug resistance-associated protein 2. Am J Transplant 2005;5:987-994.
39. van Gelder T, Klupp J, Barten MJ, Christians U, Morris RE. Comparison of the effects of tacrolimus and cyclosporine on the pharmacokinetics of mycophenolic acid. Ther Drug Monit 2001;23:119-128.
40. Rousseau A, Marquet P. Application of pharmacokinetic modeling to the routine Ther Drug Monit of anticancer drugs. Fundam Clin Pharmacol 2002;16:253-262.
41. Premaud A, Le Meur Y, Debord J, Szelag JC, Rousseau A, Hoizey G, et al. Maximum a posteriori Bayesian estimation of mycophenolic acid pharmacokinetics in renal transplant recipients at different postgrafting periods. Ther Drug Monit 2005;27:354-361.
42. van Hest R, Mathot R, Vulto A, Weimar W, van Gelder T. Predicting the usefulness of therapeutic drug monitoring of mycophenolic acid: a computer simulation. Ther Drug Monit 2005;27:163-167.